Assuntos
Morte Celular/efeitos dos fármacos , Doença Hepática Induzida por Substâncias e Drogas/fisiopatologia , Anticoncepcionais Orais Combinados/efeitos adversos , Combinação Etinil Estradiol e Norgestrel/efeitos adversos , Adulto , Doença Hepática Induzida por Substâncias e Drogas/diagnóstico , Feminino , HumanosAssuntos
Falência Hepática Aguda/induzido quimicamente , Pizotilina/efeitos adversos , Antagonistas da Serotonina/efeitos adversos , Adulto , Humanos , Falência Hepática Aguda/cirurgia , Transplante de Fígado , Masculino , Transtornos de Enxaqueca/tratamento farmacológico , Pizotilina/uso terapêutico , Antagonistas da Serotonina/uso terapêuticoRESUMO
Type II diabetes mellitus is a group of metabolic disorders of fat, carbohydrate and protein metabolism that results from defects in insulin action. It is associated with microvascular and macrovascular disease complications. Goals of therapy in management of type II diabetes mellitus are directed at reducing symptoms of hyperglycemia, reducing the onset and progression of retinopathy, nephropathy and neuropathy complications, intensive therapy of associated cardiovascular risk factors and improving quality and quantity of life. Multidisciplinary teams of health care professions are needed to optimize outcomes in persons with diabetes mellitus. This article will focus on the pharmacotherapeutic agents used in type II diabetes mellitus with or without microvascular and macrovascular disease risk. We will describe also the agents used in prevention of this disense.